All News

Meeting audience conference

Future Therapeutics for Rheumatoid Arthritis and Lessons Learned - RNL2021 Highlights

d Kathryn H. Dao, M.D.

In case you missed it, RheumNow Live 2021 delivers what it promises: a good consistent program pack with high energy interactive learning.

Read Article
pregnant.baby_.hands_.jpg

Safety of Paternal DMARD or Biologic Use

d Jack Cush, MD

A large cohort study of expectant fathers treated for immune-mediated inflammatory diseases (IMIDs) failed to show any detrimental effect from paternal exposure to immunosuppressive or biologic agents on offspring outcomes.

Read Article
gout.tophi_.jpg

RECIPE Trial - Mycophenolate to Suppress Immunogenicity with Pegloticase in Gout

d Jack Cush, MD

Pegloticase is indicated in the treatment of severe gout patients but prolonged use may be limited by immunogenicity to the PEG moiety. A randomized, controlled trial has shown that concomitant mycophenolate mofetil (MMF) may prolong the efficacy of pegloticase in gout.

Read Article
Liver.hepatitis.jpg

Liver Management in Rheumatoid Arthritis - RNL2021 Highlight

d Olga Petryna, MD

While rheumatoid arthritis (RA) is not known to affect the liver directly, underlying liver disease and treatment-related effects on the liver can often become an obstacle in the management of many RA patients. In his Sunday presentation at RNL2021, Dr.

Read Article
News Feature: RECIPE Trial - Mycophenolate to Suppress Immunogenicity with Pegloticase in Gout https://t.co/3TkjwlrSEP https://t.co/GaS8cAJijq

Links:

Dr. John Cush RheumNow ( View Tweet)
Retrospective review of 46 Rituximab treated ANCA-Assoc Vasculitis pts from 2 clinics (Mexico City, Lund) shows 24% had 18 severe infections (11.5/100 PY) - 72% within the 1st year. RTX was only independent SIE risk factor. 4 pts died, all from infection. https://t.co/8necVFP3AK

Links:

Dr. John Cush RheumNow ( View Tweet)

#RNL2021 https://t.co/5eP9OejClB

Links:

Dr. John Cush RheumNow ( View Tweet)

2020 Year in Review - Top Publications in SpA and Still’s Disease Sponsored by Novartis Medical Affairs Listen to medical experts discuss their latest insights in spondyloarthritis and Still’s disease. View Now: https://t.co/Kp2drDS1x3 https://t.co/avx5ZJ5DZb

Links:

Dr. John Cush RheumNow ( View Tweet)
Adding RTX to leflunomide works but may at ACR50 level. 140 RA pts on LEF given RTX or PBO w/ ongoing LEF. Wk 16, RTX+LEF ACR50=32% (vs PBO 15%; P=0.02), but not wk 24 (27 vs 15%), yet ACR20 was signif. RTX had more SAEs (20 vs 2%) https://t.co/t6Z9m7P2Ur

Links:

Dr. John Cush RheumNow ( View Tweet)

#RNL2021 https://t.co/5eP9Oe20X1

Links:

Dr. John Cush RheumNow ( View Tweet)

#RNL2021 https://t.co/7IKrDE2Pt5

Links:

Dr. John Cush RheumNow ( View Tweet)

News Feature: Liver Management in Rheumatoid Arthritis - #RNL2021 Highlight by Dr. Olga Petryna ( @DrPetryna ) https://t.co/OeuloE0yEd https://t.co/qYd1K0dADu

Links:

Dr. John Cush RheumNow ( View Tweet)
Survey of 500 pts with systemic rheumatic diseases during the COVID-19 pandemic showed few who discontinuations Rx - 2.2% D/C for fear of immunosuppression; 3.8% for shortages (mostly HCQ); 2.6%) for resp infx and 6% for side-effects. https://t.co/2BJIYeBSIu

Links:

Dr. John Cush RheumNow ( View Tweet)

Dr. Buch discusses the differences between difficult to treat vs refractory RA in #RNL2021. @RheumNow https://t.co/TqrHcBt0la
Dr. Rachel Tate uptoTate ( View Tweet)
"Over-achievers aren't OK with mediocrity"..."best to surround yourself with overachievers" - Joe Judge

Dr. John Cush RheumNow ( View Tweet)

Want to ask a question for the RheumNow Podcast? Record your question in 1 minute or less and we may feature it on an upcoming episode. https://t.co/hOWU67uY1Y https://t.co/ooph09KuL9

Links:

Dr. John Cush RheumNow ( View Tweet)
News Feature: Rituximab vs. JAK inhibitors in Rheumatoid Lung Disease https://t.co/2P0tdxvZD2 https://t.co/7gfE1CPSEx

Links:

Dr. John Cush RheumNow ( View Tweet)
Thanks to everyone who attended RheumNow Live 2021 in person and virtually! WE hope you enjoyed and learned from it. #RNL2021

Dr. John Cush RheumNow ( View Tweet)

Early RA pts given steroids (GC) do Not have short or long term benefits from GCs. 180 ERA pts given compared to 294 who did not. 5 yr F/U showed no differences in DAS28-CRP, HAQ or pain between groups. Steroids were used more in seronegative RA. https://t.co/CDUKDgsLRa

Links:

Dr. John Cush RheumNow ( View Tweet)

Using both glucocorticoids & PPI leads to additive risk of osteoporotic fractures - UK database studiedd 12351 RA pts - 1411 w/ OP Fx. Concomitant GCs + PPIs assoc w/ 1.6-fold risk of OP Fx (adj HR: 1.60) vs nonuse; more than 1.2-fold risk w/ either alone https://t.co/vvA6P5LEgs

Links:

Dr. John Cush RheumNow ( View Tweet)

×